BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models

DNA damaging agents cause rapid shrinkage of tumors and form the basis of chemotherapy for sarcomas despite significant toxicities. Drugs having superior efficacy and wider therapeutic windows are needed to improve patient outcomes. We used cell proliferation and apoptosis assays in sarcoma cell lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ambati, Srikanth R., Shieh, Jae-Hung, Pera, Benet, Lopes, Eloisi Caldas, Chaudhry, Anisha, Wong, Elissa W.P., Saxena, Ashish, Su, Tsann-Long, Moore, Malcolm A.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190008/
https://www.ncbi.nlm.nih.gov/pubmed/27248664
http://dx.doi.org/10.18632/oncotarget.9657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190008/
https://www.ncbi.nlm.nih.gov/pubmed/27248664
http://dx.doi.org/10.18632/oncotarget.9657

Ejemplares similares